Precision medicine answers when your patients need them most

PanTracer LBx is a minimally invasive comprehensive genomic profiling test that detects and analyzes cancer-related biomarkers. This test is performed on blood to evaluate circulating tumor DNA (ctDNA) for molecular biomarker detection to guide therapy selection and clinical trial options.

Actionable results in days

Get comprehensive genomic insights in days from minimally invasive blood draws. Enable faster clinical decisions and quicker paths to treatment when tissue is limited, inadequate, or not feasible.

Less invasive, more clarity

Eliminate the need for invasive tissue biopsies. Patients experience less anxiety and faster recovery, while your team gets the genomic insights that guide treatment decisions.

Measurable outcomes

Reduced time to biomarker results leads to better patient outcomes. Faster results mean earlier intervention, fewer delays, and care coordination that maintains patient progress.

How PanTracer LBx works for your team

Minimally invasive blood draw

Avoids invasive biopsy with blood-based testing

Within 7 days

Fast results

Actionable information in days, not weeks

500+ Genes

Comprehensive data

Genomic insights for therapy selection

Trust the experts with over 20 years of experience.

Specimen collection

Collect specimen by venipuncture according to CLSI GP41 Collection of Diagnostic Venous Blood Specimens; 7th edition.

1. **Collect 2 tubes of whole blood (10 mL per tube) from the patient.**
2. **Fill both tubes completely, to 1 inch (2.5 cm) of the stopper's bottom.**
3. **Allow 60-90 seconds for each tube to fill with blood.** Short specimens may result in partial results or cancelled testing.
4. **Gently invert each tube 10 times immediately after blood draw.**

Prevent backflow: tubes contain chemical additives and it is important to avoid backflow into the patient.

If a draw from a port is necessary, please make sure the line has been flushed of heparin. Alternatively, draw 1 mL of waste into no additive red-top or EDTA purple-top tube prior to filling the Streck Cell-Free DNA BCT® tubes.

Ready to bring PanTracer LBx to your oncology team?

Contact your NeoGenomics Sales Representative or call our Client Services team at **866.776.5907**, option 3 to get started.

Learn more about the PanTracer Portfolio: Liquid and tissue CGP testing solutions for oncologists

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

NEO GENOMICS

9490 NeoGenomics Way
Fort Myers, FL 33912

Phn: 866.776.5907
Fax: 239.690.4237

NeoGenomics.com

CORP-MRKT-0413 06.26